- Home
- EFT vs PACB Comparison
EFT vs PACB Comparison
Compare EFT & PACB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EFT
- PACB
- Stock Information
- Founded
- EFT 2004
- PACB 2000
- Country
- EFT United States
- PACB United States
- Employees
- EFT N/A
- PACB N/A
- Industry
- EFT Finance Companies
- PACB Biotechnology: Laboratory Analytical Instruments
- Sector
- EFT Finance
- PACB Industrials
- Exchange
- EFT Nasdaq
- PACB Nasdaq
- Market Cap
- EFT 327.7M
- PACB 381.5M
- IPO Year
- EFT N/A
- PACB 2010
- Fundamental
- Price
- EFT $11.94
- PACB $1.23
- Analyst Decision
- EFT
- PACB Buy
- Analyst Count
- EFT 0
- PACB 7
- Target Price
- EFT N/A
- PACB $1.90
- AVG Volume (30 Days)
- EFT 100.8K
- PACB 4.5M
- Earning Date
- EFT 01-01-0001
- PACB 11-06-2025
- Dividend Yield
- EFT 10.63%
- PACB N/A
- EPS Growth
- EFT N/A
- PACB N/A
- EPS
- EFT 1.73
- PACB N/A
- Revenue
- EFT N/A
- PACB $156,110,000.00
- Revenue This Year
- EFT N/A
- PACB $6.15
- Revenue Next Year
- EFT N/A
- PACB $15.68
- P/E Ratio
- EFT $7.62
- PACB N/A
- Revenue Growth
- EFT N/A
- PACB N/A
- 52 Week Low
- EFT $11.10
- PACB $0.85
- 52 Week High
- EFT $13.44
- PACB $2.72
- Technical
- Relative Strength Index (RSI)
- EFT 31.03
- PACB 50.49
- Support Level
- EFT $11.89
- PACB N/A
- Resistance Level
- EFT $12.05
- PACB $1.32
- Average True Range (ATR)
- EFT 0.13
- PACB 0.06
- MACD
- EFT -0.00
- PACB -0.05
- Stochastic Oscillator
- EFT 69.42
- PACB 91.11
About EFT Eaton Vance Floating Rate Income Trust of Beneficial Interest
Eaton Vance Floating-rate Income Trust is a closed-end management investment company. The company's objective is to provide a high level of current income and its secondary objective is capital appreciation.
About PACB Pacific Biosciences of California Inc.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.